We're gearing up for a busy #ASH25! The BostonGene team is excited to showcase the transformative power of our AI-driven profiling solutions. We are proud to present six abstracts in total—including two selected for oral presentation! Our research highlights how AI-powered

Join us at 4:25 PM at the #AMP2025 Innovation Spotlight Stage #2! BostonGene’s VP of R&D, Michael Goldberg and Dr. C. Ola Landgren, M.D., Ph.D. of the Sylvester Comprehensive Cancer Center, University of Miami, will host the session “AI-Data-Driven Trial Design: Advanced Digital

We’re excited to announce our collaboration with @KyotoU_News to develop advanced biological signatures that enhance targeted treatment strategies for patients with esophageal squamous cell carcinoma (ESCC). By combining BostonGene’s AI-powered, multi-scale, omnimodal platform

Join us at the Society for Immunotherapy of Cancer (@sitcancer ) 40th Anniversary Annual Meeting on November 7-8! We’ll be showcasing how our omnimodal foundation AI platform advances biomarker discovery, predicts immune response and toxicity and uncovers resistance mechanisms

Join us next week at #AMPath2025 for where we will host a session, "AI-Data-Driven Trial Design: Advanced Digital Models and Multimodal Testing Tools,” in collaboration with @SylvesterCancer, part of the University of Miami Health System and the Miller School of Medicine.

Meet us next week at the @sitcancer 40th Anniversary Annual Meeting, where we’ll showcase our research demonstrating how our omnimodal foundation AI advances biomarker discovery, predicts immune response and toxicity and reveals resistance mechanisms across cancer types.

Join us on November 5 for the 21st Annual Industry/Academia Precision Oncology & RadMed Symposium. During the symposium, Nathan Fowler, MD, Chief Medical Officer at BostonGene will present “Omnimodal AI for Precision Oncology: Integrating Data to Drive Discovery.” Dr. Fowler

BostonGene is proud to be honored with five 2025 Stevie® Awards for Technology Excellence! Our Foundation Model of Cancer and the Immune System–Led Approach was recognized for advancing precision oncology and helping biopharma de-risk drug development. Gold Stevie® Winners -

We’re excited to share how BostonGene’s multimodal AI is transforming cancer research and patient care, helping partners design smarter trials, uncover new targets and improve therapeutic response prediction across all stages of development. Meet us at #ESMO25 to learn more.

Join us this week at #ESMO25 as we showcase how our AI-powered multimodal analytics unblind tumor biology and accelerate drug development! Read more: https://t.co/PWBmy9MR7I

BostonGene has been named a Platinum Winner for AI Research Innovation at the 2025 Pinnacle Awards, recognizing our AI-powered multiomic platform for advancing discovery, patient stratification and clinical trial optimization. “We’re proud to receive this award, which highlights

We’re proud to announce our study published in Cell Reports Medicine (@CellPressNews) showcasing BostonGene’s multimodal AI solutions to stratify PD-1 and VEGF immunotherapy outcomes in kidney cancer. By integrating genomics, transcriptomics and tumor microenvironment

Join us next week at the 2025 IASLC World Conference on Lung Cancer! BostonGene will participate in a session highlighting advanced computational methods for classifying small cell lung cancer, including biomarker-defined subtypes, multiomic profiling and AI-enabled clinical

Study shows BostonGene’s Tumor Portrait™ assay—an integrated RNA-and-DNA exome test—delivers clinically robust, regulatory-grade insights across 2,200+ tumors, with actionable findings in 98% of cases, advancing precision oncology and enabling patient stratification to

Proud to be recognized as the “AI-based Drug Discovery Solution of the Year” in the 2025 AI Breakthrough Awards! Our platform is transforming oncology research and drug development by integrating high throughput tissue analytics with genomic, transcriptomic and clinical data.

Proud to share that BostonGene has received @Frost_Sullivan's 2025 Enabling Technology Leadership Award for our AI-powered platform that integrates multiomics data to accelerate discovery, reduce development risk and advance precision oncology across the entire R&D continuum!

We're proud to announce our collaboration with the @SWOG Cancer Research Network to drive personalized treatment strategies. Through this collaboration, BostonGene will provide advanced molecular profiling using our AI-powered multiomics platform to enable biomarker-driven

Join us next week at The Festival of Genomics & Biodata Boston! BostonGene will showcase how our AI-powered innovations are transforming patient-centric drug development. Discover how our advanced analytics are driving smarter, faster and more personalized approaches to cancer

Presenting 2 posters this morning at the @ASCO #ASCO25 Breast Cancer poster session — both focused on #ILC. Proud to advance lobular breast cancer research with @LobularBCA. Poster #1 (in collaboration with @BostonGeneCorp) was selected for a @GRASPtweets award! Stop by and say

It’s go time!! #ASCO25 Stop by booth #15147 to learn how BostonGene’s multimodal AI platform is accelerating oncology drug development—from biomarker discovery and patient stratification to smarter, more efficient trial design. Learn more: https://t.co/4UlM7SEDNR